tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Biogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity
PremiumRatingsBiogen: Leqembi Partnership and Subcutaneous Expansion Drive Multi‑Year Alzheimer’s Growth Opportunity
10d ago
Biogen price target raised to $233 from $217 at RBC Capital
Premium
The Fly
Biogen price target raised to $233 from $217 at RBC Capital
11d ago
Biogen price target raised to $215 from $175 at TD Cowen
Premium
The Fly
Biogen price target raised to $215 from $175 at TD Cowen
11d ago
Biogen price target raised to $246 from $185 at Guggenheim
PremiumThe FlyBiogen price target raised to $246 from $185 at Guggenheim
11d ago
Biogen, Eisai say BLA for Leqembi accepted for Priority Review by NMPA of China
Premium
The Fly
Biogen, Eisai say BLA for Leqembi accepted for Priority Review by NMPA of China
11d ago
Biogen price target raised to $201 from $191 at Bernstein
Premium
The Fly
Biogen price target raised to $201 from $191 at Bernstein
11d ago
Biogen price target raised to $190 from $156 at Morgan Stanley
PremiumThe FlyBiogen price target raised to $190 from $156 at Morgan Stanley
12d ago
Biogen price target raised to $215 from $185 at Citi
Premium
The Fly
Biogen price target raised to $215 from $185 at Citi
12d ago
Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold
Premium
Ratings
Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold
12d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100